Glucosamine Or Derivative Patents (Class 514/62)
  • Patent number: 10912788
    Abstract: Provided herein are methods of treating constipation in subjects in need thereof. The method includes administering a therapeutically effective dosage of N-acetylglucosamine. Subjects who may benefit from treatment include those having synucleinopathies, including Parkinson's Disease.
    Type: Grant
    Filed: March 7, 2019
    Date of Patent: February 9, 2021
    Assignee: PurePharm, Inc.
    Inventors: Willem Wassenaar, Alfonso Fasano
  • Patent number: 10912787
    Abstract: Methods of preventing or delaying the weakening of as well as improving the strengthening of muscles includes the step of providing an effective amount or dose of N-acetylglucosamine (GlcNAc), related saccharides, or combinations thereof both to improve myogenesis.
    Type: Grant
    Filed: July 25, 2018
    Date of Patent: February 9, 2021
    Assignee: PurePharm, Inc.
    Inventors: Sachiko Sato, Masahiko Sato, Ann Rancourt
  • Patent number: 10765698
    Abstract: This application relates to compositions comprising shortened fibers of poly-N-acetylglucosamine and/or a derivative thereof (“sNAG nanofibers”) and the use of such compositions in the treatment of disease.
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: September 8, 2020
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Patent number: 10583153
    Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.
    Type: Grant
    Filed: November 15, 2016
    Date of Patent: March 10, 2020
    Assignee: BI Investment, LLC
    Inventor: James D. Smith
  • Patent number: 10398636
    Abstract: The present invention generally relates to deuterium-enriched hyaluronan, d-HA, compositions containing the same, methods of using the same, and methods for making the same.
    Type: Grant
    Filed: December 19, 2017
    Date of Patent: September 3, 2019
    Assignee: Deuteria Biomaterials
    Inventor: Glenn Prestwich
  • Patent number: 9993496
    Abstract: Disclosed is a method for mitigating or ameliorating osteoarthritis in vertebrate subjects including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation. Also disclosed is an oral or parenteral hyaluronan composition comprising a polydisperse hyaluronan and a pharmaceutically acceptable carrier, and a method of manufacturing the composition.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: June 12, 2018
    Assignee: Reyn Pharma, LLC
    Inventor: James D. Smith, Jr.
  • Patent number: 9558231
    Abstract: Systems, methods, and other embodiments associated with a data view for clinical data are described. In one embodiment, a method includes receiving a request from a user to view summarized case report form (CRF) data, where the CRF data corresponds to a plurality case report forms (CRFs) stored in one or more normalized transactional tables. A view query is constructed based, at least in part, on the request and executed on one or more denormalized summary tables to construct a view. The denormalized summary tables store selected CRF data from the normalized transactional tables and are updated concurrently with each update to the transactional tables. The method includes rendering the view for display.
    Type: Grant
    Filed: May 22, 2013
    Date of Patent: January 31, 2017
    Assignee: ORACLE INTERNATIONAL CORPORATION
    Inventors: Scott Shepard, Hanan Butler, Paul Boyd, Paul Bradford, Sai K. Lee, Michael T. O'Connell, Roxanne Chang, Christopher Luu
  • Patent number: 9375703
    Abstract: Provided are biomass-based materials and valuable uses of microalgal biomass including: (i) acetylation of microalgal biomass to produce a material useful in the production of thermoplastics; (ii) use of triglyceride containing microalgal biomass for production of thermoplastics; (iii) combination of microalgal biomass and at least one type of plant polymer to produce a material useful in the production of thermoplastics; (iv) anionization of microalgal biomass to form a water absorbant material; (v) cationization of microalgal biomass, and optional flocculation, to form a water absorbant material; (vi) crosslinking of anionized microalgal biomass; (vii) carbonization of microalgal biomass; and (viii) use of microalgal biomass in the making of paper.
    Type: Grant
    Filed: December 21, 2012
    Date of Patent: June 28, 2016
    Assignee: Solazyme, Inc.
    Inventors: Ali Harlin, Anna-stiina Jääskeläinen, Jani Kiuru, Christiane Laine, Tiina Liitiä, Kalle Nättinen, Jaakko Pere, Sonia Sousa, John Piechocki, Adrienne McKee, Jeffrey J. Cernohous, Adam R. Pawloski
  • Patent number: 9339528
    Abstract: The invention provides a use of the interleukin-1 receptor antagonist protein for preparing a medicament for preventing or treating epithelium trauma of the intestinal mucosa, wherein the protein is selected from: (a) a protein having an amino acid sequence as shown in SEQ ID NO: 1; (b) a protein which has a sequence having at least 70% homology with the amino acid sequence in the (a) and has the effect of preventing or treating epithelium trauma of the intestinal mucosa. The invention also provides a pharmaceutical composition comprising the protein (a) or (b) as the active component.
    Type: Grant
    Filed: October 26, 2010
    Date of Patent: May 17, 2016
    Assignee: GENERAL REGENERATIVES, LTD.
    Inventors: Wei Han, Di Xiang, Zhenqian Wu
  • Patent number: 9320682
    Abstract: There are described tooth filling materials and dental varnishes for inhibiting the biofilm formation of Streptococcus mutans containing (a) a quantity of an active substance for inhibiting the biofilm formation, (b) a material for forming a structure for the uptake and delayed release of the active substance and (c) a filling material system. Another aspect of this invention relates to a method for producing tooth filling materials or dental varnishes according to the invention for inhibiting the biofilm formation of Streptococcus mutans. The present invention also relates to a kit comprising tooth filling materials or dental varnishes according to the invention and one or more additional constituents. There are also described methods for inhibiting the biofilm formation of Streptococcus mutans, methods for producing a dental component which inhibits the biofilm formation and the use of the active substance for producing a dental material.
    Type: Grant
    Filed: August 9, 2013
    Date of Patent: April 26, 2016
    Assignee: VOCO GMBH
    Inventors: Irene Wagner-Doebler, Andree Barg
  • Patent number: 9320653
    Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to achieve hemostasis at an increased rate. More specifically the present invention relates to hemostatic compositions that achieve a hemostatic effect at a distance from the site of application of the composition, and a method for administering such a composition to effectively reduce localized vascular complications associated with treating a breach or puncture in a vein or artery and reduce the time to achieve hemostasis.
    Type: Grant
    Filed: August 13, 2014
    Date of Patent: April 26, 2016
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: John N. Vournakis, Sergio Finkielsztein
  • Patent number: 9302982
    Abstract: Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds and methods of their use.
    Type: Grant
    Filed: July 17, 2012
    Date of Patent: April 5, 2016
    Assignee: GLYCON LLC
    Inventor: Samuel T. Christian
  • Patent number: 9215888
    Abstract: Nutritional compositions, formulations, and intermediates are provided which may be utilized to formulate various sweeteners and other products. The formulations described herein are made from constituents found in soils or fossilized soils.
    Type: Grant
    Filed: April 24, 2013
    Date of Patent: December 22, 2015
    Inventors: Albert Duoibes, Carl Nannini
  • Patent number: 9132143
    Abstract: An individual at risk for necrotizing enterocolitis and related disorders can be identified by measuring the level of at least one secretor antigen in a biological sample from the individual and comparing the measured level of the at least one secretor antigen to a predetermined value or a predetermined range of values. Among the secretor antigens which can be measured are: the H-1, H-2, Lewisb and Lewisy antigens and derivatives thereof (e.g., a sialylated form of Lewis a, Lewis x, Lewis b, Lewis y; H-1, H-2, Lewis a, Lewis x, Lewis b or Lewis y).
    Type: Grant
    Filed: September 23, 2014
    Date of Patent: September 15, 2015
    Assignees: The General Hospital Corporation, Instituto Nacional de Ciencias Medicas Y Nutricion, Children's Hospital Medical Care
    Inventors: Ardythe L. Morrow, David S. Newburg, Guillermo M. Ruiz-Palacios
  • Patent number: 9056121
    Abstract: Disclosed is a method for the amelioration of osteophyte formation including administering to a subject a therapeutically effective amount of an exogenous hyaluronan formulation.
    Type: Grant
    Filed: March 12, 2012
    Date of Patent: June 16, 2015
    Assignee: Reyn Pharma, LLC
    Inventor: James D. Smith
  • Patent number: 9040503
    Abstract: A method of promoting recovery of cell viability of a damaged respiratory cell. The method includes a step of administering to the cell at least one pharmaceutically acceptable compound, which accelerates sialyglycoconjugate biosynthesis to restore sialylglycoconjugates on the surface of the respiratory cell. Also disclosed are a method and a pharmaceutical composition, both for treating a respiratory condition.
    Type: Grant
    Filed: July 2, 2010
    Date of Patent: May 26, 2015
    Assignee: Australian Biomedical Company Pty Ltd.
    Inventors: Betty Jin, Paul Arthur Jones, Ee Ling Seah, Wen Yang Wu, Peter James Jenkins
  • Publication number: 20150132280
    Abstract: A human dietary supplement comprises theacrine and optionally other compounds that modulate the effects of theacrine. Uses for the theacrine-containing supplement include improvement of at least one of mood, energy, focus, concentration or sexual desire or a reduction of at least one of anxiety or fatigue.
    Type: Application
    Filed: November 12, 2014
    Publication date: May 14, 2015
    Applicant: ORTHO-NUTRA, LLC
    Inventors: Hector L Lopez, Shawn Wells, Tim N. Ziegenfuss
  • Publication number: 20150111850
    Abstract: The invention relates to the treatment of an inflammatory or immune disorder with a pharmaceutical composition including methylsulphonylmethane, glucosamine and glycine or pharmaceutically acceptable salts or derivatives of these compounds.
    Type: Application
    Filed: April 2, 2013
    Publication date: April 23, 2015
    Inventor: Paul Frederick Turner
  • Patent number: 9012430
    Abstract: Disclosed are compositions and formulations comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and adapted for use in a bath or soak or bath beads, powders, salts, and oils, kits, and methods of treatment using the same. Also disclosed are lozenges, suppositories, patches, and topical creams comprising glucosamine or a pharmaceutically acceptable salt thereof for use in the treatment of joint conditions and methods of treatment using the same. In some embodiments the joint conditions include osteoarthritis.
    Type: Grant
    Filed: March 12, 2013
    Date of Patent: April 21, 2015
    Assignee: Vital Medicine, LLC
    Inventors: Anjan Chatterji, Grant Cooper, David Schwartz
  • Patent number: 8999954
    Abstract: The invention relates to inhibitors of polysialic (PSA) de-N-acetylase, methods of their production and use. The methods involve use of a PSA de-N-acetylase inhibitor for modifying the growth of cells, such as inhibiting the growth of cancer cells. The compositions include an inhibitor of a PSA de-N-acetylase, such as N-substituted derivatives of the amino sugars hexosamine and neuraminic acid, as well as conjugates and aggregates. Also provided are pharmaceutical compositions that include a PSA de-N-acetylase inhibitor of the invention. Kits containing one or more inhibitor compositions of the invention, as well as methods of preparing the compositions also are provided.
    Type: Grant
    Filed: July 3, 2008
    Date of Patent: April 7, 2015
    Assignee: Childern's Hospital & Research Center at Oakland
    Inventors: Gregory R. Moe, Brent T. Hagen
  • Patent number: 8986746
    Abstract: The present document describes methods of use of photo activated compositions for oral disinfection and/or treatments which comprise at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmacologically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 24, 2015
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis
  • Patent number: 8987232
    Abstract: Provided are effective and highly safe agents, medicaments and the like for ameliorating various disorders caused by brain hypofunction. Also provided is a preventing or ameliorating agent for brain hypofunction containing N-acetyl-D-mannosamine, a pharmaceutical composition for preventing, ameliorating or treating disorders due to brain hypofunction, containing an effective amount of N-acetyl-D-mannosamine and a pharmaceutically acceptable carrier, and a food comprising N-acetyl-D-mannosamine added thereto.
    Type: Grant
    Filed: February 25, 2011
    Date of Patent: March 24, 2015
    Assignees: The University of Tokyo, School Corporation, Azabu Veterinary Medicine Educational Institution
    Inventors: Kunio Shiota, Masayoshi Kuwahara, Takefumi Kikusui, Shintaro Yagi
  • Patent number: 8986745
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 24, 2015
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Publication number: 20150072953
    Abstract: The present disclosure provides mixtures of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both capable of modulating joint inflammation, joint pain, joint stiffness, cartilage degradation, or improving mobility, range of motion, flexibility, joint physical function, or any combination thereof. Such a mixture of prenylated flavonoids, stilbenes, or both with flavans or curcuminoids or both can optionally be used in combination with other joint management agents, such as non-steroidal anti-inflammatory agents/analgesics, COX/LOX inhibiting agents, glucosamine compounds, neuropathic pain relief agents, or the like.
    Type: Application
    Filed: June 16, 2014
    Publication date: March 12, 2015
    Inventors: Lidia Alfaro Brownell, Min Chu, Mei-Feng Hong, Eu-Jin Hyun, Qi Jia, Ping Jiao, Hyun-Jin Kim, Mi-Ran Kim, Tae-Woo Kim, Bo-Su Lee, Young-Chul Lee, Breanna Moore, Jeong-Bum Nam, Mi-Sun Oh, Mi-Hye Park, Mesfin Yimam, Qian Zhang
  • Patent number: 8974833
    Abstract: There is provided a wound healing composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin in association with a pharmaceutically acceptable carrier. In addition, a method of topically treating wounds using at least one oxidant and at least one photoactivator capable of activating the oxidant followed by illumination of said photosensitizer is disclosed.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: March 10, 2015
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Publication number: 20150057245
    Abstract: This invention provides for the use of compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 2 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond in treating a subject suffering from a disease associated with harmful angiogenic processes such as cancer.
    Type: Application
    Filed: October 29, 2014
    Publication date: February 26, 2015
    Inventor: SAUL YEDGAR
  • Patent number: 8962595
    Abstract: Compositions containing a small molecule therapeutic and an alkyl N,N-disubstituted amino acetate are disclosed. Inclusion of the alkyl N,N-disubstituted amino acetate enhances the pharmacokinetic properties of the small molecule therapeutic.
    Type: Grant
    Filed: May 4, 2011
    Date of Patent: February 24, 2015
    Assignee: Nexmed Holdings, Inc.
    Inventors: Bassam B. Damaj, Richard Martin
  • Patent number: 8951565
    Abstract: Improved hemostatic agents take the form of granules or particles that can be used to stanch, seal, or stabilize a site of hemorrhage, including a noncompressible hemorrhage.
    Type: Grant
    Filed: April 17, 2014
    Date of Patent: February 10, 2015
    Assignee: HemCon Medical Technologies, Inc.
    Inventor: Simon J. McCarthy
  • Patent number: 8951990
    Abstract: Described herein are methods for treating a dental disorder in a subject comprising administering to the subject an effective amount of a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with a C1-C10 unsubstituted alkyl group or fluoroalkyl group.
    Type: Grant
    Filed: January 7, 2013
    Date of Patent: February 10, 2015
    Assignee: University of Utah Research Foundation
    Inventors: Glenn Prestwich, Jianxing Zhang, Sr., Thomas P. Kennedy, Narayanam Rao
  • Patent number: 8946194
    Abstract: The application of a highly controlled, micron-sized, branched, porous architecture to enhance the handling properties and degradation rate of hydrogels is described in the instant invention. A previously described pattern created through one-step nucleated crystallization in a hydrogel film creates tunable mechanical properties and/or chemical stability for use in tissue engineering applications. The bulk mechanical properties and the degradation rate of the material can be tuned easily by the addition or subtraction of crystalline structure or by the addition and subtraction of backfill material, making this useful for a variety of applications. Relevant mechanical properties that can be tuned through the application of this unique porosity are moduli, elasticity, tensile strength, and compression strength. The method of the present invention can be applied to biopolymers and natural materials as well as synthetic materials.
    Type: Grant
    Filed: October 7, 2011
    Date of Patent: February 3, 2015
    Assignee: Board of Regents, University of Texas System
    Inventors: Sarah Mayes, Christine E. Schmidt
  • Publication number: 20150031646
    Abstract: A carrier enhancing absorption of medication includes a target medication, an emulsifier, a small-molecular hyaluronic acid (HA) component, an absorption enhancer and a cream base, wherein the carrier promotes infiltration of target medication from skin over affected area and enhance the absorption efficacy of human body by synergistic interaction.
    Type: Application
    Filed: July 25, 2013
    Publication date: January 29, 2015
    Inventor: MING-CHEN LEE
  • Publication number: 20150024996
    Abstract: Pharmaceutical compositions for intraocular injection are described, the compositions consisting essentially of a therapeutically effective quantity of an anti-bacterial agent (such as moxifloxacin), a therapeutically effective quantity of an anti-inflammatory agent (such as triamcinolone), at least one pharmaceutically acceptable excipient and a pharmaceutically acceptable carrier. Methods for fabricating the compositions and using them for intraocular injections are also described.
    Type: Application
    Filed: March 27, 2014
    Publication date: January 22, 2015
    Applicant: IMPRIMIS PHARMACEUTICALS, INC.
    Inventors: Jeffrey T. LIEGNER, John Scott Karolchyk, Bernard Covalesky, Richard Dilzer, Kallan Peters
  • Patent number: 8937052
    Abstract: The present invention relates generally to the field of therapeutics and in particular, chemotherapy. Even more particularly, the present invention provides therapeutic strategies which reduce the toxicity or enhance the efficacy of chemotherapeutic agents. Compositions and methods of treatment and prophylaxis are also contemplated by the present invention.
    Type: Grant
    Filed: July 27, 2006
    Date of Patent: January 20, 2015
    Assignee: Alchemia Oncology Pty Limited
    Inventor: Tracey J. Brown
  • Patent number: 8933055
    Abstract: The antimicrobial composition of the present invention comprises a cationic active ingredient, a quaternized sugar-derived surfactant, and an optional foam boosting surfactant. These formulations have a high cidal activity in a short amount of time and provide stable copious foam. The formulations of the present invention also exhibit enhanced tissue (e.g. skin) compatibility as defined by an in vitro whole toxicology assessment method.
    Type: Grant
    Filed: September 21, 2011
    Date of Patent: January 13, 2015
    Assignee: Ecolab USA Inc.
    Inventors: Daniel E. Pedersen, Angela R. Eder, Charles A. Hodge
  • Publication number: 20150010627
    Abstract: The present invention relates to new pharmaceutical compositions of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to new pharmaceutical compositions for use in the treatment of pain and inflammatory symptoms associated with joint and cartilage disorders, especially with osteoarthritis and rheumatoid arthritis.
    Type: Application
    Filed: January 29, 2013
    Publication date: January 8, 2015
    Inventors: Umit Cifter, Ali Turkyilmaz, Onur Mutlu, Gaye Ramazanoglu
  • Publication number: 20150011486
    Abstract: Glycosylated antitumor ether lipids (GAELs) are effective cytotoxic agents against cancer stem cells. Furthermore, combining GAELs which kill cells by a caspase-independent pathway with agents that kill cells by apoptosis will lead to elimination of the differentiated tumor cells and the undifferentiated cancer stem cells leading to an elimination of the tumor and preventing recurrence.
    Type: Application
    Filed: February 8, 2013
    Publication date: January 8, 2015
    Inventors: Gilbert Arthur, Frank Schweizer, Pranati Samadder, Yaozu Xu
  • Publication number: 20140377350
    Abstract: Bilayer Tablet Formulations of Flurbiprofen And Glucosamin The present invention relates to a bilayer tablet formulation of flurbiprofen and glucosamine. Particularly, the present invention relates to a bilayer tablet formulation having a controlled release flurbiprofen and immediate release glucosamine; furthermore relates to their process and use.
    Type: Application
    Filed: January 28, 2013
    Publication date: December 25, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Onur Mutlu
  • Publication number: 20140377320
    Abstract: A treated surface of a device (10) for implantation or for application as a wound dressing, comprises an array of plasma-activated hydrophilic cell-adhesive areas (18) having the ability to reduce fibrous reaction, is in the form of an array of islets of activation. Each islet of activation (18) has a length which is less than 6 ?m, a width which is less than 2 ?m and the distance between islets is preferably from 4 ?m to 6 ?m. The islets of activation (18) are surrounded by non-activated, non-adhesive, hydrophobic areas.
    Type: Application
    Filed: December 21, 2012
    Publication date: December 25, 2014
    Inventors: Giorgio Pietramaggiori, Hicham Majd
  • Patent number: 8916544
    Abstract: Described herein are fatty acid carbohydrate-hydroxyl-hybrid compounds and derivatives thereof, and methods of treating or preventing disease and disease symptoms using the compounds and compositions thereof.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: December 23, 2014
    Assignee: The Johns Hopkins University
    Inventors: Kevin J. Yarema, Udayanath Aich, Christopher Thomas Campbell, Srinivasa-Gopalan Sampathkumar, Sean S. Choi, Michael Adam Meledeo, Christopher Weier
  • Patent number: 8911791
    Abstract: There is provided a skin rejuvenation composition which comprises at least one oxidant, at least one photoactivator capable of activating the oxidant, and at least one healing factor chosen from hyaluronic acid, glucosamine and allantoin, in association with a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: December 16, 2014
    Assignee: KLOX Technologies Inc.
    Inventors: Remigio Piergallini, Nikolaos Loupis, Francesco Bellini
  • Patent number: 8912166
    Abstract: An ophthalmic preparation and method, usable to treat conjunctivochalasis. The ophthalmic preparation comprises an aqueous solution of glycerol. The preparation may also include additional components including high molecular weight polymers for viscosity control and pharmacologically active substances. The method includes administering an ophthalmic preparation including an aqueous solution of glycerol to a patient.
    Type: Grant
    Filed: November 5, 2013
    Date of Patent: December 16, 2014
    Assignee: Resdevco Research and Development Co. Ltd.
    Inventor: Shabtay Dikstein
  • Publication number: 20140363508
    Abstract: The present invention relates to pharmaceutical formulations of flurbiprofen or a pharmaceutically acceptable salt thereof and glucosamine or salts thereof. Particularly, the present invention relates to a stable formulation of this combination having desired levels of dissolution rate and solubility which comprises at least one polymer having a low glass transition temperature.
    Type: Application
    Filed: December 20, 2012
    Publication date: December 11, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Onur Mutlu
  • Publication number: 20140349964
    Abstract: The invention provides a method for producing an orexin neuron by culturing a pluripotent stem cell or a neural progenitor cell in the presence of N-acetyl-D-mannosamine and optionally in the presence of at least one inhibitor selected from the group consisting of a Sirtuin 1 inhibitor and an O-linked ?-N-acetylglucosamine transferase inhibitor. The invention also provides a therapeutic agent for narcolepsy or eating disorders, such as anorexia, containing N-acetyl-D-mannosamine, which is based on the induction of orexin neuron in vivo.
    Type: Application
    Filed: March 25, 2014
    Publication date: November 27, 2014
    Inventors: Kunio SHIOTA, Shintaro YAGI, Koji HAYAKAWA, Mitsuko HIROSAWA-TAKAMORI, Daisuke ARAI, Keiji HIRABAYASHI
  • Publication number: 20140336148
    Abstract: The present invention relates to novel pharmaceutical combinations with synergistic action of diacerein or a pharmaceutically acceptable salt of diacerein and non-steroidal inflammatory drugs, having analgesic, anti-inflammatory, antipyretic, and osteoarthritis-treating activities.
    Type: Application
    Filed: December 25, 2012
    Publication date: November 13, 2014
    Inventors: Umit Cifter, Ali Turkyilmaz, Nur Pahlivan Akalin, Sibel Zenginer, Onur Mutlu
  • Publication number: 20140328775
    Abstract: A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include batyl alcohol, undecylenoyl phenylalanine, hexyldecanol, and bisabolol. A method of reducing the synthesis of melanin by using the cosmetic compositions is also disclosed herein.
    Type: Application
    Filed: May 1, 2014
    Publication date: November 6, 2014
    Applicant: The Procter & Gamble Company
    Inventors: Leo Timothy LAUGHLIN, II, Tomohiro HAKOZAKI, Shuhei TANAKA
  • Patent number: 8877684
    Abstract: A composition comprising at least a compound (a) of general formula (I): and an insecticide compound (b) in a (a)/(b) weight ratio of from 1/1 to 1/1013. A composition further comprising an additional fungicidal compound. A method for preventively or curatively combating the pests and diseases of crops and increasing their yield by using this composition.
    Type: Grant
    Filed: December 11, 2007
    Date of Patent: November 4, 2014
    Assignee: Bayer CropScience AG
    Inventors: Heike Hungenberg, Wolfgang Thielert, Jean-Pierre Vors
  • Patent number: 8871247
    Abstract: The present invention relates generally to the field of hemostasis, including methods, compositions, and devices that can be employed to treat wounds. More specifically the present invention relates to hemostatic compositions that reduce the need for, and cost of, nursing care of patients with chronic wounds by reducing the frequency of wound dressing changes.
    Type: Grant
    Filed: February 19, 2008
    Date of Patent: October 28, 2014
    Assignee: Marine Polymer Technologies, Inc.
    Inventors: Sergio Finkielsztein, John N Vournakis
  • Patent number: 8871742
    Abstract: The present invention provides a composition, and a method of use thereof, for treating connective tissue damage in man and in animals, which comprises a therapeutically effective amount of chondroitin sulfate, N-acetyl D-glucosamine, and hyaluronan (hyaluronic acid). Particularly, the present invention provides a composition, and a method of use thereof, for treating connective tissue damage including, but not limited to, arthritic disease, osteoarthritis, rheumatoid arthritis, osterochondrosis dessicans, cartilage damage, joint injury, joint inflammation, joint synovitis, degenerative joint disease (DJD), post surgical DJD, traumatic injury, fracture, tendon damage, ligament damage, skeletal damage, musculoskeletal damage, fiber damage, adipose tissue damage, blood cell damage, and plasma damage. Compositions for delivery of the present invention include those for parenteral, oral, and transmucosal delivery and for direct surgical placement onto the affected tissues.
    Type: Grant
    Filed: May 10, 2013
    Date of Patent: October 28, 2014
    Assignee: ArthroDynamic Technologies, Animal Health Division, Inc.
    Inventors: Frank D. Marcum, John William Seanor, Foster Harold Northrop
  • Patent number: 8871744
    Abstract: The present invention relates to pharmaceutical compositions containing tumor-selective targeted inhibitor glycoconjugates. These bioconjugates are ALK5 inhibitors covalently bound to biocompatible carrier molecules which selectively target and specifically bind to Muc4 that is overexpressed on a variety of tumor cell types. The ALK5 inhibitors are conjugated to tumor targetable glycans through a covalent linker. Preferably the acid-labile linker is designed to be stable in plasma and releases pharmacologically active inhibitors through acid-catalyzed hydrolysis in the acidic environment of the target tumor where the inhibitor activity is restored. Because the glycoconjugates are stable at physiological pH and in plasma, they advantageously reduce undesirable systemic ALK5 inhibitor activity; however, the preferable glycoconjugates are acid-labile conjugates that can be hydrolyzed upon reaching the more acid environment of the tumor.
    Type: Grant
    Filed: July 18, 2011
    Date of Patent: October 28, 2014
    Assignee: B & G Partyers, LLC
    Inventor: Donald L. Barbeau
  • Patent number: 8865681
    Abstract: In one embodiment, the invention provides a method of treating, reducing the incidence, reducing the severity or pathogenesis of an eye disease or disorder in a subject, including, inter alia, retinal detachment, macular degeneration, glaucoma or retinopathy, comprising the step of administering an effective amount of a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof. This invention also provides a contact lens solution comprising a lipid or phospholipid moiety bound optionally via a spacer to a physiologically acceptable monomer, dimer, oligomer, or polymer via an ester or amide bond, and/or a pharmaceutically acceptable salt or a pharmaceutical product thereof.
    Type: Grant
    Filed: November 14, 2007
    Date of Patent: October 21, 2014
    Assignee: Yissum Research Development Company of the Hebrew Unitersity of Jerusalem
    Inventors: Saul Yedgar, Yuval Cohen